Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 11/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4294076 | 0.93 | SIGMAR1 (0.39) | SIGMAR1SCN9ASCN10A | |
| SCHEMBL4281841 | 0.89 | KMT2A (0.39) | SIGMAR1SCN9ASCN10ATLR9TLR7 | |
| SCHEMBL8104556 | 0.87 | CXCR4 (0.39) | SIGMAR1TLR9 | |
| SCHEMBL4289498 | 0.82 | TLR7 (0.39) | APPTLR9MGLLTLR7CHRNA7 | |
| SCHEMBL4289860 | 0.81 | GAA (0.41) | SIGMAR1SCN9ASCN10A | |
| SCHEMBL4293422 | 0.81 | SMN1; SMN2 (0.43) | MGLLCHRNA7 | |
| SCHEMBL4285366 | 0.81 | HSP90AA1 (0.38) | SCN9ASCN10A | |
| SCHEMBL4752778 | 0.81 | RAB9A (0.44) | — | |
| SCHEMBL4281703 | 0.81 | RAB9A (0.44) | — | |
| Hydrochloric Acid SCHEMBL4289031 | 0.80 | SMN1; SMN2 (0.43) | MGLLCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | SIGMAR1 3163/4885APP 1773/4885SCN9A 1866/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | SIGMAR1 3163/4885APP 1773/4885SCN9A 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.